Aberdeen Group
ALXO icon

Aberdeen Group’s ALX Oncology ALXO Stock Holding History

Aberdeen Group’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-66,211
Closed -$41.2K – 954
2025
Q1 		$41.2K Hold
66,211
– – ﹤0.01% 939
2024
Q4 		$111K Hold
66,211
– – ﹤0.01% 927
2024
Q3 		$121K Hold
66,211
– – ﹤0.01% 912
2024
Q2 		$399K Hold
66,211
– – ﹤0.01% 877
2024
Q1 		$738K Hold
66,211
– – ﹤0.01% 844
2023
Q4 		$986K Buy
+66,211
New +$628K ﹤0.01% 836

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Aberdeen Group's ALXO Position: Q2 2025 in Review

Aberdeen Group sold out of ALX Oncology (ALXO) in Q2 2025, closing a stake of 66,211 shares — an estimated $41.2K sold.

Aberdeen Group first reported a position in ALXO in Q4 2023 and held it in 6 quarters. The position peaked at $986K in Q4 2023. 61 funds tracked by Wall St. Rank hold ALXO as of Q2 2025.

  • Aberdeen Group reported no remaining ALX Oncology position as of Q2 2025 after selling out during the quarter.
  • Aberdeen Group sold 66,211 ALX Oncology shares in Q2 2025, an estimated $41.2K.
  • Aberdeen Group first reported a position in ALX Oncology in Q4 2023 and held it in 6 quarters.
  • Aberdeen Group's ALX Oncology position peaked at $986K in Q4 2023.
  • 61 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2025.

Based on Aberdeen Group's 13F filing for Q2 2025, filed 24 Jul 2025.